Eli Lilly has launched a new multi-dose version of its popular obesity drug Zepbound, giving patients a full month’s worth of injections in a single pen device. The new KwikPen, which holds four weekly doses, became available Monday (February 23) through Lilly’s direct-to-consumer platform, LillyDirect, for self-paying patients with a valid prescription.
Cash-paying customers can get the KwikPen starting at $299 per month for the lowest 2.5-milligram dose. The pen is available in all six dose levels — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — with prices capping at no more than $449 per month.
“As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines,” Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, said in a statement.
Until now, patients taking Zepbound had to use a different single-dose auto-injector pen each week, or draw the medication themselves from a vial using a syringe. The KwikPen simplifies that process by combining four weekly doses into one reusable device, reducing the number of items patients need to manage each month.
The same KwikPen technology is already used to deliver Lilly’s widely prescribed diabetes drug, Mounjaro. The U.S. Food and Drug Administration (FDA) approved a label expansion for the multi-dose Zepbound format in late January, alongside a similar approval for Mounjaro KwikPens. The device has also been available in the United Kingdom, Australia, the Middle East, and Canada.
The new KwikPen prices align with reductions Lilly made in December to its single-dose Zepbound vials. At that time, the company cut self-pay prices across all vial dosages by between $50 and $150. Lilly previously agreed with the Trump administration to cap multi-dose KwikPen prices at no more than $449 for self-pay patients, as part of a broader effort to bring U.S. drug prices more in line with those in other countries.
For now, the KwikPens are only available through LillyDirect for self-paying patients. Patients using commercial insurance may only choose the prefilled single-dose pen option through the platform. Lilly has not announced a timeline for making the KwikPen available through traditional pharmacy channels.
Recent Comments